Get the Stockscreener App
0.68
1.46%
-0.0101
After Hours:
.70
0.02
+2.94%
Mink Therapeutics Inc stock is traded at $0.68, with a volume of 35,615.
It is down -1.46% in the last 24 hours and down -5.56% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
See More
Previous Close:
$0.6901
Open:
$0.69
24h Volume:
35,615
Relative Volume:
1.01
Market Cap:
$26.89M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-0.8831
EPS:
-0.77
Net Cash Flow:
$-17.36M
1W Performance:
-9.81%
1M Performance:
-5.56%
6M Performance:
-32.00%
1Y Performance:
-35.24%
1-Day Range:
$0.6707
$0.71
1-Week Range:
$0.6661
$0.7612
52-Week Range:
$0.57
$1.90
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| INKT | 0.68 | 26.89M | 0 | -24.77M | -17.36M | -0.77 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Mink Therapeutics Inc Stock (INKT) Latest News
Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World
Comparing Fractyl Health (GUTS) and Its Peers - Defense World
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Bio-Path Holdings Reports Third Quarter 2024 Financial Results and Expansion into Obesity Program - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MiNK Therapeutics Sets Q3 2024 Earnings Call: iNKT Cell Therapy Updates Ahead | INKT Stock News - StockTitan
Hedge funds pile into banks, dump green energy post US election, Goldman Sachs says - Yahoo Canada Finance
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 - GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid - The Bakersfield Californian
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
CAR-T Cell Therapy Competitive Landscape 2024 (Updated) - openPR
MiNK Therapeutics announces executive transition By Investing.com - Investing.com Australia
MiNK Therapeutics announces executive transition - Investing.com India
Renaissance Technologies LLC Makes New Investment in Team, Inc. (NYSE:TISI) - Defense World
Rx Rundown: AstraZeneca, Danco Laboratories, GSK and more - MM+M Online
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous - Investing.com Canada
Mink Therapeutics and Autonomous Therapeutics target metastatic tumors through new collaboration - BioWorld Online
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):